Working… Menu
Trial record 4 of 25 for:    "Lens Disease" | "Nepafenac"

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03499873
Recruitment Status : Completed
First Posted : April 17, 2018
Last Update Posted : June 5, 2019
Information provided by (Responsible Party):
Actavis Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 31, 2018
Actual Study Completion Date : December 18, 2018